Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

3.670 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
Via Benzinga
Amylyx: An "Ice Bucket" Buy
The drug was green-lighted by the Food & Drug Administration last month, after clinical trials partially funded by Ice Bucket Challenge grants showed that Relyvrio takers had a median survival period... 
Via Talk Markets
Where Amylyx Pharma Stands With Analysts
Analysts have provided the following ratings for Amylyx Pharma (NASDAQ:AMLX) within the last quarter: 
Via Benzinga
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field. 
Via Investor's Business Daily
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Launch of Public Offering
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System
Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB),  Alector Inc. 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Bounce In Futures Fizzles As Dollar Surge Returns
In premarket trading, Nike shares fall 10% after the sportswear giant cut its margin outlook for the year while reporting surging inventory, fueling worries over consumers’ ability to spend as... 
Via Talk Markets
Why Is IONQ Stock Up 8% Today?
IonQ (IONQ) stock is climbing higher on Friday after the company announced it secured a $13.4 million contract with the AFRL. 
Via InvestorPlace
AMLX Stock Alert: Amylyx Pharma Gains on Huge FDA Win
Shares of Amylyx Pharma are popping today on news that the FDA has greenlit its treatment against the deadly disease ALS. 
Via InvestorPlace
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) rose 42% to $3.21 in pre-market trading after dipping 26% on Thursday. SAI.TECH recently announced the launch of new liquid cooling Bitcoin mining... 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.